Clinical Trial

CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-24; most recent amendment 2026-04-10.
Trial Details
NCT Number NCT06617286
Lead Sponsor New York Medical College
Collaborators: University of North Carolina
Conditions Classical Hodgkin Lymphoma
Enrollment 21 participants
Start Date 2026-12-01
Primary Completion 2039-12-31 (estimated)
Study Completion 2040-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-15